Iovance Biotherapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell IOVA and other ETFs, options, and stocks.

About IOVA

Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. 

CEO
Frederick G. Vogt
CEOFrederick G. Vogt
Employees
838
Employees838
Headquarters
San Carlos, California
HeadquartersSan Carlos, California
Founded
2007
Founded2007
Employees
838
Employees838

IOVA Key Statistics

Market cap
1.15B
Market cap1.15B
Price-Earnings ratio
-2.40
Price-Earnings ratio-2.40
Dividend yield
Dividend yield
Average volume
7.82M
Average volume7.82M
High today
$3.16
High today$3.16
Low today
$2.90
Low today$2.90
Open price
$2.86
Open price$2.86
Volume
937.41K
Volume937.41K
52 Week high
$5.88
52 Week high$5.88
52 Week low
$1.64
52 Week low$1.64

Stock Snapshot

As of today, Iovance Biotherapeutics(IOVA) shares are valued at $3.03. The company's market cap stands at 1.15B, with a P/E ratio of -2.40.

During the trading session on 2026-02-24, Iovance Biotherapeutics(IOVA) shares reached a daily high of $3.16 and a low of $2.90. At a current price of $3.03, the stock is +4.5% higher than the low and still -4.1% under the high.

Trading activity shows a volume of 937.41K, compared to an average daily volume of 7.82M.

The stock's 52-week range extends from a low of $1.64 to a high of $5.88.

The stock's 52-week range extends from a low of $1.64 to a high of $5.88.

IOVA News

TipRanks 53m
Iovance Biotherapeutics reports Q4 EPS (18c), consensus (18c)

Reports Q4 revenue $86.711M, consensus $81.01M. Frederick Vogt, Ph.D., J.D., Interim President and Chief Executive Officer of Iovance, stated, “Iovance delivere...

TipRanks 1h
Iovance Biotherapeutics announces results from trial for TIL cell therapy

Iovance Biotherapeutics (IOVA) announced positive early data from a pilot clinical trial led by Memorial Sloan Kettering Cancer Center, MSKCC, and supported by...

Simply Wall St 6d
Is Real‑World Amtagvi Response Data Altering The Investment Case For Iovance Biotherapeutics?

In early February 2026, Iovance Biotherapeutics reported real-world retrospective data showing a best-in-class clinical profile and unprecedented response rates...

Is Real‑World Amtagvi Response Data Altering The Investment Case For Iovance Biotherapeutics?

Analyst ratings

64%

of 11 ratings
Buy
63.6%
Hold
36.4%
Sell
0%

People also own

Based on the portfolios of people who own IOVA. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.